Na-K/2Cl transporter inhibition for reduction of postischemic kidney failure tested in autologous reperfusion
Postischemic kidney function may be influenced by donor conditioning. The sulfamoylbenzoate “piretanide” (P) is a diuretic agent with an inhibitory effect on the luminal Na-K-2CL-transporter system in the ascending part of the loop of Henle. A clinical pilot study demonstrated a lower rate of organ dysfunction following transplantation in humans when the donor organs were pretreated with piretanide. In an experimental ex vivo model the effect of piretanide on immediate organ function following long or short cold ischemia was studied. Porcine kidneys (n = 36) were removed after in situ transaortal hypothermic flushing with 21 Eurocollins solution. Following short storage (1 h, n = 18) or long storage (24 h, n = 18) the kidneys were reperfused with intraoperatively drawn heparinized autologous blood diluted with Ringer's lactate to a hematocrit of 25%. Urine flow was higher in the piretanide-pretreated group (p), especially after long storage. The electrolyte loss was comparable in both groups. Postischemic endogenous creatinine clearance was significantly elevated in the treatment group (4.45 ± 0.6 ml/min per 100 mg in P vs 1.91 ± 0.4 ml/min per 100 mg, in control, P < 0.05 Mann-Whitney test). Renal hemodynamics were improved by piretanide, resulting in significantly lower resistance and allowing higher flow during pressurecontrolled perfusion. O2 consumption, representing general metabolic activity, was higher after long storage, indicating an earlier recovery from cold ischemia. In this ex vivo model, autologous reperfusion of porcine kidneys could be improved by piretanide pretreatment. Autoregulation of kidney vasculature was maintained as well as functional parameters such as creatinine clearance or gluconeogenesis. Therefore, piretanide may be used in larger clinical trials to further improve organ quality in times of donor shortage.
Key wordsPiretanide Kidney transplantation Donor conditioning Ex vivo hemoperfusion
Unable to display preview. Download preview PDF.
- 1.Abendroth D, Pooth R, Schneeberger H, Land W (1993) Effects of piretanide on early graft function in kidney transplantation — a pilot study. Transplant Proc 25: 2626 - 2627Google Scholar
- 2.Booster M, Yin M, Kurvers HAJM, et al (1995) Inhibition of CD18-dependent leukocyte adherence by mAb 6.5 E does not prevent ischemia-reperfusion injury as seen in grafted kidneys. Transplant Int 8: 126 - 132Google Scholar
- 7.Kaplan MP, Toledo-Pereya LH, Pietro-ski R, et al (1986) Transplant Proc 18: 504 - 505Google Scholar
- 8.Kirsten R, Alexandridis T, Heintz B, et al (1987) Elsevier 365-368Google Scholar
- 9.Klaus E, Alpermann MG, Caspritz G, Linz W, Scholkens B (1983) Vascular effects of piretanide. Studies on extra-renal action in several animal models. Arzneim Forsch 33: 1273-1276Google Scholar
- 11.Marone C, Reubi FC, Lahn W (1984) Comparison of the short-term effects of the loop diuretic piretanide and furosemide in patients with renal insufficiency. Eur J Clin Pharmacol 26: 413418Google Scholar
- 12.Rocher LL, Landers C, Dafoe DC, et al (1987) The importance of prolonged post-transplant dialysis requirement in cyclosporine-treated renal allograft recipients. Clin Transplant 1: 29 - 36Google Scholar
- 14.Schneeberger H, Schleibner S, Schilling M, et al (1990) Prevention of acute renal failure after kidney transplantation by treatment with rh-SOD: interim analysis of a double-blind placebo controlled trial. Trnasplant Proc 22: 2224–2225Google Scholar
- 15.Storck M, Sirsjö A, Abendroth D, Hammer C (1995) Laser perfusion imaging (LPI) — a new method of monitoring microcirculation in postischemic organ reperfusion. (submitted)Google Scholar
- 16.Storck M, Schilling M, Steinbach G, Abendroth D Influence of systemic cyclooxygenase inhibition with single dose aspisol (ASA) on kinetics of arachidonic acid metabolism in the venous effluate of transplanted kidney grafts in humans. Transplant Proc (in press)Google Scholar